Trial Profile
A Phase 1 Randomized, Double-Blind Placebo Controlled Study to Evaluate the Safety and Immunogenicity of the LIve Oral Cholera Vaccine Candidate PXVX0200 Vibrio Cholerae Serotype 01 Inaba CVD 103-HgR Vaccine Strain
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Jun 2023
Price :
$35
*
At a glance
- Drugs PXVX 0200 (Primary)
- Indications Cholera
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Bavarian Nordic
- 16 Jul 2012 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 30 Apr 2012 New trial record